文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

阿司匹林预防或治疗ARDS:临床前模型综述与临床研究Meta分析

Prevention or Treatment of Ards With Aspirin: A Review of Preclinical Models and Meta-Analysis of Clinical Studies.
PubMed 文献 · Shock · 2017-01-01
一句话结论临床前研究显示阿司匹林可能有益,3项临床研究Meta分析显示阿司匹林使用与ARDS发生率降低相关(OR 0.59,95%CI 0.36-0.98),但现有数据不足以支持将阿司匹林用于ARDS适应症。

该研究系统综述了阿司匹林在肺损伤中的临床前研究,并对临床研究进行Meta分析。检索Medline、Embase和Cochrane数据库,共纳入15项临床前研究和8项临床研究。动物研究显示阿司匹林总体效果积极,可改善生存、减轻炎症和肺水肿,高剂量阿司匹林可能是首选药物。3项临床研究的Meta分析显示阿司匹林使用与ARDS发生率降低相关(OR 0.59,95%CI 0.36-0.98),但存在显著的研究间异质性。作者认为现有数据不足以支持阿司匹林用于ARDS的适应症,但支持进一步开展人体研究。

要点

  • 3项临床研究Meta分析显示阿司匹林使用与ARDS发生率降低相关(OR 0.59,95%CI 0.36-0.98),但研究间异质性显著。
  • 动物研究显示阿司匹林总体效果积极,可改善生存、减轻炎症和肺水肿。
  • 高剂量阿司匹林可能是首选药物(原文作者基于临床前研究提出)。
  • 所有纳入研究均存在方法学质量方面的缺陷。
  • 作者认为现有数据不足以支持将阿司匹林用于ARDS适应症,但支持进一步开展人体研究。

研究设计与关键结果

  • 研究类型:临床前研究系统综述与临床研究Meta分析;检索Medline、Embase、Cochrane数据库,共检索到1314篇文献,最终纳入15项临床前研究和8项临床研究。
  • 动物研究:阿司匹林总体效果积极,可改善生存、减轻炎症和肺水肿;作用机制包括干扰中性粒细胞-血小板相互作用、减少白三烯、中性粒细胞胞外诱捕网和前列腺素。
  • 临床研究Meta分析:3项临床研究显示阿司匹林使用与ARDS发生率降低相关(OR 0.59,95%CI 0.36-0.98),但研究间异质性显著。
  • 所有纳入研究均存在各自的方法学质量缺陷。

证据类型、等级与局限

  • 证据类型:临床前研究系统综述与临床研究Meta分析。
  • 局限:所有研究均存在各自的方法学质量缺陷;临床研究Meta分析存在显著的研究间异质性。

对床旁实践的改变

  • 作者认为现有数据不足以支持将阿司匹林用于ARDS适应症。
  • 作者建议在开展前瞻性随机试验之前,先进行临床试验评估阿司匹林在肺损伤模型中的作用机制,以指导最佳时机和剂量。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The acute respiratory distress syndrome (ARDS) is a life-threating disorder that contributes significantly to critical illness. No specific pharmacological interventions directed at lung injury itself have proven effective in improving outcome of patients with ARDS. Platelet activation was identified as a key component in ARDS pathophysiology and may provide an opportunity for preventive and therapeutic strategies. We hypothesize that use of acetyl salicylic acid (ASA) may prevent and/or attenuate lung injury.

METHODS: We conducted a systematic review of preclinical studies and meta-analysis of clinical studies investigating the efficacy of ASA in the setting of lung injury. Medline, embase, and cochrane databases were searched.

RESULTS: The literature search yielded 1,314 unique articles. Fifteen preclinical studies and eight clinical studies fulfilled the in- and exclusion criteria. In the animal studies, the overall effect of ASA was positive, e.g., ASA improved survival and attenuated inflammation and pulmonary edema. Mechanisms of actions involved, among others, are interference with the neutrophil-platelets interaction, reduction of leukotrienes, neutrophil extracellular traps, and prostaglandins. High-dose ASA may be the drug of choice. A meta-analysis of three clinical studies showed an association between ASA use and a reduced incidence of ARDS (OR 0.59, 95% CI 0.36-0.98), albeit with substantial between-study heterogeneity. All studies had their own shortcomings in methodological quality.

CONCLUSION: This systematic review of preclinical studies and meta-analysis of clinical studies suggests a beneficial role for ASA in ARDS prevention and treatment. However, the currently available data is insufficient to justify an indication for ASA in ARDS. The body of literature does support further studies in humans. We suggest clinical trials in which the mechanisms of action of ASA in lung injury models are being evaluated to guide optimal timing and dose, before prospective randomized trials.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Panka BA, de Grooth HJ, Spoelstra-de Man AM, et al. Prevention or Treatment of Ards With Aspirin: A Review of Preclinical Models and Meta-Analysis of Clinical Studies. Shock. 2017. PMID: 27984533

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。